Gilead Sciences, Inc. Price Today
Gilead Sciences, Inc.
GILD
Healthcare
$98.14B
💰
Market Cap
17.8
💸
Price to Earnings
$4.4
🎉
EPS
+78
🌳
ESG
Consensus Recommendations
Buy Consensus
Buy |
13 |
Strong Buy |
5 |
Hold |
19 |
Sell |
0 |
Strong Sell |
0 |
GILD Price Forecast Target
78.7 👉 104.3 +33%
GILD EPS Forecast
4.4 👉 6.5 +47%
Financials
Profit Margin
20 %
Revenue Growth
5.4 %
Dividend
$ 3.0
Held Percent
0.1% - Insiders
86.8% - Institutions
13.1% - Public
Major Fund Holders
-
💰 Blackrock Inc. $10.0B
-
💰 Vanguard Group Inc $8.9B
-
💰 Capital World Investors $6.0B
-
💰 Capital Research Global Investors $4.6B
-
💰 State Street Corporation $4.5B
Stock Ideas
Ron Baron Portfolio
Ron Baron is an American billionaire investor, entrepreneur, and the founder of Baron Capital Group, a well-known investment management firm. He is recognized for his long-term, growth-oriented investment approach and has built a successful track re…
Stanley Druckenmiller Portfolio
Stanley Druckenmiller is a legendary hedge fund manager who has made billions of dollars for his investors. His current portfolio is heavily invested in gold, silver, and other precious metals. He also owns shares in several technology and healthcar…
Michael Platt Portfolio
Michael Platt is the founder and CEO of BlueCrest Capital Management, a global macro hedge fund with a focus on systematic trading strategies. Prior to starting BlueCrest, Platt worked as a portfolio manager and trader, gaining experience across glo…
Seth Klarman Portfolio
Seth Klarman's investment prowess is exemplified by his exceptional track record. Since the inception of his fund until 2008, he achieved an impressive compound return-on-investment of 20%. This remarkable achievement showcases his astute investment…📮FAQ
Some Frequently Asked Questions.
The Gilead Sciences, Inc. industry is Drug Manufacturers—General
The Gilead Sciences, Inc. sector is Healthcare
The Gilead Sciences, Inc. forecasted predicted Price to Earnings PE ratio is 12.1
The Gilead Sciences, Inc. Price to Earnings PE ratio is 17.8
The Market Capitalization of Gilead Sciences, Inc. is $98.14B
There are total of 1244668657 float shares with 86.8% held by Institutions and 0.1% held by insiders
The MGilead Sciences, Inc. forecasted Earnings per Share EPS is $6.5
The Gilead Sciences, Inc. Earnings per Share EPS is 4.4
The Gilead Sciences, Inc. company has $21624000000 gross profits with 20 profit margins
The Gilead Sciences, Inc. Earnings Growth is -0.088% with -0.087% quarterly earnings growth
The Gilead Sciences, Inc. Revenue is $27381999616 with 0.054 revenue growth
The price target for Gilead Sciences, Inc. stock is $104.3 for the high target and $69.8 for the low target
The consensus analyst recommendations for Gilead Sciences, Inc. is Buy, however the decision to buy or sell the stock should be entirely yours, as you are earning your own money and hence responsible on how to allocate and spend them.
The consensus analyst recommendations for Gilead Sciences, Inc. is Buy, with the following breakdown:
- Buy: 13
- Strong Buy: 5
- Hold: 19
- Sell: 0
- Strong Sell: 0
The Beta of Gilead Sciences, Inc. is 0.4
The dividend of Gilead Sciences, Inc. is $3.0
The dividend yield of Gilead Sciences, Inc. is 0.0381%
The biggest institutional and mutual fund holders of Gilead Sciences, Inc. stock are
- Blackrock Inc.
- Vanguard Group Inc
- Capital World Investors
- Capital Research Global Investors
The Gilead Sciences, Inc. ESG Score is 78, with the following breakdown:
- E: 0.03
- S: 14.04
- G: 8.01